Introduction
Umbilical cord blood stem cell transplantation (UCBSCT) for primary immunodeficiencies (PIDs) is placed in the context of other new developments in the field. The historical reasons for the dramatic improvement in outcome after haematopoietic stem cell transplantation (HSCT) for PIDs is outlined, cord blood biology reviewed, and the advantages and disadvantages of UCBSCT for PIDs discussed, noting ready availability of the unit, lower risk of graft vs. host disease (GvHD) despite a degree of human leukocyte antigen (HLA) mismatch and higher frequency of unusual HLA types compared with bone marrow registries, naivety of lymphocytes against disseminated viral infection, prolonged immune reconstitution as well as low stem cell dose for recipients over 15 kg. Clinical outcome data and likely future developments are reviewed.
Haematopoietic stem cell transplantation for primary immunodeficiencies
Genetically inherited disorders of innate or adaptive immunity usually present in early childhood and frequently lead to severe or fatal complications. The most serious, severe combined immunodeficiencies (SCIDs), present in early infancy and without treatment are fatal by the age of 1 year. These disorders affect development and/or function of T lymphocytes, and sometime B lymphocytes and natural killer cells. Other combined immunodeficiencies such as Wiskott-Aldrich syndrome, CD40 ligand deficiency or innate system disorders, such as chronic granulomatous disease, are less immediately life threatening, but registry data indicate poor longterm outlook. At the same time, allogeneic HSCT is now more successful in curing lethal forms of immunodeficiency with long-term survivors leading normal lives, often off all medication. Thus, the range of conditions treated by HSCT has considerably broadened. Initially only patients who had an HLA-identical relative were transplanted as HSCT using other donors was considered to carry too great a risk of fatal GvHD.
Unrelated HLA-matched donor transplants were first performed in the 1970s. The first active bone marrow donor registry (The Anthony Nolan Trust) was established in 1974. Now over 10 million volunteer stem cell donors are registered worldwide. In 1981, the introduction of T lymphocyte depletion to remove alloreactive lymphocytes from the bone marrow source enabled transplantation across HLA barriers. This meant that patients without an HLA-identical donor could receive T lymphocyte-depleted marrow from an HLA-haploidentical parent. More recent innovations such as use of granulocyte colony-stimulating factor-mobilized peripheral blood HSCs, concentration of diagnosis and treatment in specialized centres, early identification of infection using PCR techniques, more effective antiviral and antifungal treatments (including infusion of cytotoxic T lymphocytes specific for Epstein-Barr virus, cytomegalovirus and adenovirus), better treatment of GvHD, including the use of monoclonal antibodies such as infliximab and basiliximab, in combination with improved supportive care, have improved the success rate for HSCT for SCID from 40 to 80% for HLA-haploidentical transplantation.
The use of UCBSCs for HSCT needs evaluating in this context. The first UCBSCT was performed in 1988 for Fanconi's anaemia [1] . International bone marrow donor registries are increasingly holding data on donated cord blood. A cord blood bank was established in 1993 in New York; currently more than 200 000 cord blood units are stored in 37 cord blood banks.
Cord blood biology
Whilst solid organ transplant recipients require lifelong immunosuppression to prevent graft rejection, HSCT grafts usually become tolerant of recipients, eliminating the need for long-term immunosuppression. When tolerance does not develop fully, however, acute or chronic GvHD ensues. Cord blood T lymphocytes seem to become more readily tolerant to host HLA antigens than bone marrow T lymphocytes, which may reduce the risk and severity of GvHD for a given degree of HLA mismatch following UCBSCT. Cord blood T lymphocytes remain tolerant to the host despite retaining alloreactivity to third-party cells [2] .
Increased tolerance associated with functional immaturity of dendritic cells
Initiation of acute GvHD is mediated by CD8
þ T lymphocytes dependent on residual host antigenpresenting cells, but intensified by donor antigenpresenting cells, such as dendritic cells. CD4 þ T lymphocytes are particularly important in chronic GvHD. There are fewer plasmacytoid dendritic cells and myeloid dendritic cells in cord blood, and they are more likely to express an immature or tolerogenic phenotype characterized by low expression of major histocompatibility II and costimulatory molecules. Interferon-a and tumor necrosis factor-a production is diminished in cord blood immature myeloid dendritic cell and plasmacytoid dendritic cells, and immature dendritic cells from cord blood are also potent inducers of CD4 þ T regulatory cells [3 ] .
Functional immaturity of umbilical cord blood lymphocytes
Activated UCB lymphocytes produce lower amounts of cytokines after stimulation compared with activated adult T lymphocytes, including lower amounts of interferon-g and tumor necrosis factor-a, important inducers of GvHD. UCB lymphocytes produce less interleukin-2 and -4 as well as demonstrating less antigen-specific cytotoxicity. There are lower levels of expression in genes activated by the nuclear factor of activated T lymphocytes pathway, many of which are responsible for cellular activation and differentiation [4] . birth weight, particularly when this exceeds 3000 g. There is a trend towards increased CD34 þ cell content in cord blood from Caucasian mothers [7 ] .
Antigen-specific T lymphocyte function
Naïve T lymphocytes present in cord blood are capable of generating T lymphocytes with specificity for herpes viruses within the first 100 days after transplantation. Standard immunosuppression (cyclosporin and steroids) does not appear to interfere with development of antigen specific T lymphocytes. As cord blood does not contain antigen-specific memory T lymphocytes, the antigenspecific T lymphocytes detected during the first 12 months after cord blood are most likely derived from the naïve T lymphocytes infused at the time of transplantation [8 ] .
Infectious complications
Infection is a risk during three phases of HSCT:
Pre-engraftment: bacterial and fungal infection due to neutropenia, lymphopenia, mucositis, central venous catheters and acute GvHD. After engraftment: viral reactivations occur, particularly cytomegalovirus and adenovirus. After day þ100: relatively immature cellular and humoral immunity mean varicella zoster virus and pneumococcal infections are a risk.
In the first 100 days post-UCBSCT, the risk of bacterial infection is diminished compared to other HSCT, but the risk of viral death is increased, even when compared to recipients of T cell-depleted marrow. This is perhaps unsurprising, as despite in-vitro data showing that UCB T lymphocytes develop antiviral responses, unlike T lymphocytes from adult donors, UCB T lymphocytes will not have encountered viruses such as Epstein-Barr virus, cytomegalovirus and adenovirus, so in-vivo responses will be poor in the first 100 days post-UCBSCT. There is a significantly higher risk of needing two or more courses of ganciclovir to treat cytomegalovirus reactivation after cord blood compared to other HSC sources. Human herpes virus 6 viraemia is most notable during weeks 2 and 3 following transplantation, and infection is more frequently observed among cord blood recipients with prior primary infection and higher viral load. UCBSCT recipients are more likely to die of viral infection in the first 100 days than recipients of T lymphocytedepleted marrow. After day 100 there is no excess in infective deaths in UCBSCT recipients and no significant difference in the incidence of severe fungal infection regardless of HSC sources. The risk of serious infection among children receiving cord blood grafts is comparable to that of unmanipulated marrow and is lower than that of a T lymphocyte-depleted stem cell source. Among adult patients, despite an overall higher incidence of serious infections after cord blood compared with unrelated donor grafts, nonrelapse mortality and overall survival were not significantly different between HSC sources [9 ] .
Advantages and disadvantages of umbilical cord blood transplantation
There are a number of advantages of UCBSC over other HSC sources, but also some disadvantages.
Advantages
Advantages are listed in Table 1 and include the following.
Rapid access to the donor unit
Whilst a matched unrelated donor needs to be identified, assessed and harvested, a cord blood unit is already cryopreserved and can be at the transplant centre within a matter of days. The median time from search to availability for cord blood was 13.5 days (range 2-387 days) compared with 49 days (range 32-293 days) for a bone marrow donor in one study [10] . Rapid identification of a donor is important when transplanting infected immunodeficient patients, particularly those with SCID.
Ease of arranging date for transplantation
As the cord blood unit is readily available, the transplantation date and conditioning protocol is easily planned without reference to donor or harvest list availability.
No medical risk to the donor
The risk of bone marrow harvest to the donor is very small but finite, whereas there is no risk to donating UCBSC.
Lower risk of latent viral transmission
There is a lower risk of latent viral transmission from the donor to the recipient because most neonates are virologically naïve.
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Lower risk of graft vs. host disease
There is a lower risk of GvHD and it is possible to perform transplants with two or three HLA antigen mismatches.
Higher frequency of rare HLA haplotypes compared to bone marrow registries
There is a higher frequency of rare HLA types represented on the cord blood registries as individuals from ethnic minorities carrying these types are more likely to donate UCBSC than bone marrow. This is particularly helpful in PIDs where there is an excess of ethnic minority patients due to consanguinity.
Stem cell nascence
The HSC telomere length is longer in patients who have received UCBSCs than in those who have received peripheral blood stem cells from older donors. UCBSCs may have greater self-renewing capacity and longevity than those derived from an adult donor. As many transplanted PID patients are infants or young children, giving HSCs with a greater proliferative lifespan is theoretically more attractive. Long-term studies will determine whether this is clinically relevant.
Disadvantages
Disadvantages to use of UCBSCs are listed (Table 1) and include the following.
Lack of availability of the donor for a boost haematopoietic stem cell transplantation
Low-intensity conditioning regimens are increasingly employed in patients with significant organ damage at time of transplant; whilst transplant-related mortality may be reduced, donor chimerism may decrease over time and rescue strategies including infusion of further mature T lymphocytes or stem cells from the original donor can rescue and reverse this decrease in chimerism. Once UCBSCs have been transplanted, further HSCs cannot be obtained from the original donor, except perhaps when a family relative was the donor.
Lack of viral-specific cytotoxic T lymphocytes
Whilst viral naivety of the neonate reduces the risk of transmitting virus from the donor to the recipient, it also means there are no activated virologically competent antigen-specific T lymphocytes within the cord to immediately neutralize disseminated viral infection in the transplant recipient. As many PID patients come to transplantation with disseminated infection, the time to clearance of virus is thus delayed and may result in a poor outcome.
Reduced stem cell dose

A CD34
þ stem cell dose of 1.7 Â 10 5 /kg is recommended for transplant, as lower doses are associated with slower, poor engraftment. UCBSC units contain finite cell counts; in one study, the median CD34 þ cell count would be satisfactory for a 12-kg individual [7 ] .
Slower engraftment
Engraftment tends to be slower in patients who have received cord blood related to the lower stem cell dose. This may have disadvantages in terms of effective immunity against infection, but may be preferable where there is widespread mycobacterial disease or inflammation, e.g. maternofoetal engraftment or Omenn syndrome where slower engraftment with more naïve, less readily activated cells may lead to less inflammation at the time of engraftment and therefore improved patient survival.
Risk of transmitting unidentified genetic disease
There is a theoretical risk of transmitting a genetic disease to the recipient if it has not been identified in the donor.
Umbilical cord blood haematopoietic stem cell transplantation for primary immunodeficiency
There are now many papers from a large number of centres describing UCBSCT for PIDs. There are detailed reports of 30 UCBSCTs for SCID with 77% survival and GvHD incidence of 30% (17% in six of six HLA matches) ( Table 2 ).
There are detailed reports of 60 UCBSCTs for other PIDs, with 85% survival and GvHD incidence of 38% (3% in six of six HLA matches) (Table 3 ). There is incomplete information on a number of other patients [19 ] . A variety of conditioning regimens have been used successfully, including myeloablative and reduced intensity conditioning protocols. Severe (grade III/IV) GvHD was uncommon, occurring in only 6% of patients. Two deaths were associated with GvHD and three patients experienced chronic GvHD; 100% donor chimerism and normal immune reconstitution is normally achieved. Mortality was due to various factors including infection (n ¼ 3), veno-occlusive disease (n ¼ 1) and chronic lung disease (n ¼ 3). In our own practise, 20 children have received UCBSCT (13 SCID). Sixteen were six of six HLA-matched -no grade III/IV GvHD was experienced. All patients engrafted. Overall survival was 70%. There was 100% B lymphocyte function in evaluable patients. We prefer UCBSCs to T cell-depleted haploidentical HSCT in SCID patients and will accept a five of six HLA match. For larger patients with preexisting viral infection, the choice is more difficult and UCBSC are used less often.
Future developments
The place of UCBSCT for PIDs is now well established. Strategies to overcome the disadvantages of using UCBSCs are now being developed to widen the potential use (Table 4) . The low stem cell dose and the associated risk of poor engraftment is the greatest challenge. Double or multiple UCBSC unit infusion has shown early, promising results with quicker engraftment [50, 51 ]. Ex-vivo expansion of UCB-derived T lymphocytes, whilst retaining a naïve and/or central memory phenotype with polyclonal T cell receptor diversity, may augment cord blood transplantation and improve rate and extent of immune reconstitution [52 ] . A phase I trial in humans has demonstrated safety, although there was no change in time to engraftment [53] . Phase II studies are underway.
Coinfusion of purified HSCs [54, 55 ] or mesenchymal cells [56 ,57 ] derived from cord blood or third parties is currently being studied. This may improve engraftment and reduce GvHD. Other potential developments include the ex-vivo development of UCB-derived regulatory T cells [58 ] and viral antigen-specific T lymphocytes.
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